Mind Moments®, a podcast from NeurologyLive®, brings you exclusive commentary from Alberto J. Espay, MD, PhD, and Anton P. Porsteinsson, MD. [LISTEN TIME: 48 minutes]
The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.
Episode 94, "The Discussion Surrounding Lecanemab's Approval for Alzheimer Disease," features an in-depth dive into the recent approval of lecanemab (Leqembi; Eisai) for Alzheimer disease and the ongoing debate about its potential benefit, the amyloid-targeting class of medicines, and the communication of data. Featured in this episode is commentary from 2 experts in neurology clinical care: Anton P. Porsteinsson, MD, the William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine, and the director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester School of Medicine and Dentistry; and Alberto Espay, MD, PhD, the division director and Research Endowed Chair of the James J. and Joan A. Gardner Family Center for Parkinson’s Disease and Movement Disorders, and a professor of clinical neurology and rehabilitation medicine at the University of Cincinnati.
This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com
The stories and studies featured in this week's show, as well as additional expert interviews on lecanemab, can be found here:
Additional reading and coverage:
Additional expert interviews:
Click here to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!
Hoping to listen on your favorite podcast app? See below: